Syndax Pharmaceuticals Receives Moderate Buy Rating from Bloomberg Ratings Amidst Growing Interest from Institutional Investors
Syndax Pharmaceuticals, Inc. has recently received an average rating of "Moderate Buy" from Bloomberg Ratings. Eight analysts are presently covering ...